--- title: Administration of DHEA in Patients With Poor Response to Ovarian Stimulation for IVF nct_id: NCT02099916 overall_status: UNKNOWN phase: PHASE2, PHASE3 sponsor: University of Athens study_type: INTERVENTIONAL primary_condition: Efficacy of DHEA canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02099916.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02099916" ct_last_update_post_date: 2014-09-10 last_seen_at: "2026-05-12T06:40:29.885Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Administration of DHEA in Patients With Poor Response to Ovarian Stimulation for IVF **Official Title:** Prospective Randomized Trial on the Effect of DHEA Administration in Women With Poor Ovarian Reserve Undergoing Controlled Ovarian Stimulation for IVF. Impact on Stimulation Characteristics and and Pregnancy Outcome. **NCT ID:** [NCT02099916](https://clinicaltrials.gov/study/NCT02099916) ## Key Facts - **Status:** UNKNOWN - **Phase:** PHASE2, PHASE3 - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 50 - **Lead Sponsor:** University of Athens - **Collaborators:** Lito Maternity Hospital - **Conditions:** Efficacy of DHEA, Pregnancy Rate, Diminished Ovarian Reserve, Changes in AMH - **Start Date:** 2014-10 - **Completion Date:** 2015-12 - **CT.gov Last Update:** 2014-09-10 ## Brief Summary Poor responders to ovarian stimulation represents one of the most frustrating problems in reproductive medicine. The investigators hypothesize that ovarian response of those patients could improve by treating these patients with 25 mg DHEA tid for 12 weeks prior to stimulation. ## Detailed Description Patients diagnosed with poor ovarian response will be included in the study. The definition of poor response was based on the presence of at least one of the following criteria: Age \> 40 years old, day 2 FSH \>9.5 mIU/ml, AMH \< 2ng/ml ,at least one previous COH with less than 3 oocytes retrieved, at least one cancelled attempt due to poor response, estradiol less than 500 pg/ml on the day of HCG. All patients will be counseled regarding their prognosis and other treatment options including oocyte donation as well as adoption were also presented and discussed in detail. All patients will be aware that the use of DHEA is experimental and informed consent was obtained for those agreeing to use the medication. Women in the DHEA group will receive 25 mg of DHEA three times a day for at least 12 weeks. During this period, women will be subjected to monthly measurements of early follicular phase FSH and estradiol. Anti-Mullerian Hormone (AMH) will be measured prior to the initiation of treatment and at the end of the observation period. Patients will be stimulated with a short GnRH-antagonist protocol. Briefly, all women will have measurements of serum FSH and estradiol and a pelvic sonogram on the second day of their cycle. Providing that serum FSH is \< 17 mIU/ml and estradiol is \< 70 pg/ml on day 2 , ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH. All patients will be re-evaluated on day 5 of the stimulation, and dosage adjustments will be made and the antagonists (Cetrorelix or ganirelix 0.25 mg/day) will be initiated. When at least 2 follicles reach an average diameter of 17 mm, final oocyte maturation will be triggered with 10,000IU of hCG ( Pregnyl, Organon, Greece Inc.). Oocyte retrieval will be performed 34 to 36 hours later. All patients will undergo ICSI. Patients with successful fertilization will have embryo transfer under sonographic guidance on day 3 after retrieval. ## Eligibility - **Minimum age:** 20 Years - **Maximum age:** 50 Years - **Sex:** FEMALE - **Healthy Volunteers:** Yes ``` Inclusion Criteria: * Women with poor response to ovarian stimulation. The definition of poor response was based on the presence of at least one of the following criteria: Age \> 40 years old, day 2 FSH \>9.5 mIU/ml, AMH \< 2ng/ml ,at least one previous COH with less than 3 oocytes retrieved, at least one cancelled attempt due to poor response, estradiol less than 500 pg/ml on the day of HCG. Exclusion Criteria: * All other women that do not fulfill the above mentioned criteria ``` ## Arms - **gonadotropins plus DHEA** (ACTIVE_COMPARATOR) — Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists. Prior to the stimulation will be treated with DHEA 25 mg PO tid for 12 weeks. - **Gonadotropins** (ACTIVE_COMPARATOR) — Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists. ## Interventions - **gonadotropins plus DHEA** (DRUG) — Women in the DHEA group will received 25 mg of DHEA three times a day for at least 12 weeks. - **Gonadotropins** (DRUG) — All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH. ## Primary Outcomes - **clinical pregnancy** _(time frame: At 12 weeks after DHEA administration and at 18 months)_ — At the completion of the ovarian stimulation patients that will proceed to transfer and have a positive pregnancy test will have sonographic evaluation for confirmation of clinical pregnancy. ## Secondary Outcomes - **changes in ovarian reserve indexes** _(time frame: 6 months)_ ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `sponsor.collaborators` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT02099916.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT02099916* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*